Hemostemix received FDA support for its basket protocol approach, a regulatory milestone the company says will streamline the development of its platform across multiple indications. The endorsement lets Hemostemix test a shared protocol framework to accelerate enrollment and comparative assessments across heterogeneous patient groups. For developers of cell- and tissue-based therapies, FDA backing of basket designs can reduce duplicative trial infrastructure and shorten timelines for signal detection across rare indications. The decision underscores continued regulatory openness to adaptive and platform trial structures in regenerative-medicine development.